HT941026N0107 NOI NHO AMICUS Cell Separator Sys Consumables.pdf
PDF 126 KB Posted
- Solicitation number
- HT941026N0107
- Issued by
-
Defense Health Agency
About this file
This is a Notice of Intent to Sole Source a supply contract for FDA Fenwal Amicus Apheresis Reagents. The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – West, intends to award a firm-fixed-price purchase order to Fenwal, Inc. (UEI: E9UHXHZCGJV5, CAGE: 4Q7Q2) for drop shipment of Intercept platelet small volume processing sets and platelet dual storage containers. The procurement supports operational requirements of Naval Hospital Okinawa, Japan, and is classified under NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing) with a business size standard of 1,250 employees. The product service code is 6550 (In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets). The requested items are vital for collection, treatment, and sustainment of blood platelet inventory for patient care and are mandated by FDA for pathogen reduction of donated blood platelets. Fenwal, Inc. is identified as the sole manufacturer and provider capable of meeting minimum requirements.
Delivery is scheduled for October 1, 2026, through September 30, 2027, with delivery to MAB, DLA Troop Support Xdock West Project, c/o Cardinal Health MPS Distribution Center, 4551 East Philadelphia Street, Ontario, California 91761. Interested vendors may challenge the basis of this sole source award by submitting capability statements (maximum four pages, 8.5" x 11" format, 10-point font minimum) including management, technical, and cost data with evidence of capability. Submissions must be emailed as Microsoft Word or Adobe PDF attachments to Mariangela Monsalve (mariangela.j.monsalve.civ@health.mil) or Bobbie Dobberstein (bobbie.s.dobberstein.ctr@health.mil) by 1000 Pacific Daylight Time, Friday, August 28, 2026. Requests for documentation or inquiries consisting solely of questions will not be considered affirmative responses. The Government reserves discretion to determine whether to conduct competitive procurement or proceed with sole-source purchase order based on responses received.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Notice of Intent to Sole Source HT941026N0107
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT
AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.
The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – West (HCD-W), intends to award a firm-fixed-price purchase order for Drop Shipment of FDA Fenwal Amicus Apheresis Reagents (Manufacturer: Fenwal, Inc.). This procurement supports the operational requirements of Naval Hospital Okinawa, Japan, and is conducted in accordance with Federal Acquisition Regulation (FAR) 12.102(a), this acquisition of commercial products and services is being executed as a sole source, as the Contracting Officer does not have a reasonable expectation that two or more offers will be received.
FENWAL, INC.
3 CORPORATE DR STE 300
LAKE ZURICH, IL 60047-8930, United States
UEI: E9UHXHZCGJV5
CAGE: 4Q7Q2
The North American Industry Classification System (NAICS) code for this requirement is 325413, In-Vitro Diagnostic Substance Manufacturing, which has a business size standard of 1,250 employees. The product service code (PSC) is 6550, In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets.
The objective of this sole source award is to procure Amicus Apheresis reagents for the cell separator for Naval Hospital Okinawa, located at Bldg 960, Tarawa Road, Camp Foster, Okinawa, Japan.
The requested Intecept platelet small volume processing set and platelet dual storage containers are used in the Intercept pathogen reducing equipment. These items are vital in the collection, treatment and sustainment of adequate inventory of blood platelets products for routine and emergent patient care and mission requirement. Pathogen reduction of donated blood platelet products reduces the transmission of viruses and infections upon transfusion. US Naval Hospital Okinawa PACOM Armed Services Blood Bank Center (ASBBC) is mandated by FDA to conduct pathogen reduction process for all collected blood platelets. Supplies of the platelet sets are historically sustained thru a drop shipment contract. The suggested vendor is the sole manufacturer and provider of the platelet sets.
Fenwal, Inc., is the only source capable of meeting the government’s minimum requirements.
Delivery Period: 1 October 2026 through 30 September 2027
Delivery Location: MAB, DLA TROOP SUPPORT XDOCK WEST PROJECT, C/O CARDINAL
HEALTH MPS DISTRIBUTION CENTER, 4551 EAST PHILADELPHIA STREET, ONTARIO
CA 91761
This notice of intent is not a request for competitive proposals, and no formal solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement. Submissions must include management, technical, and cost data in sufficient detail accompanied by convincing evidence to clearly demonstrate the capability to provide the required equipment and preventive maintenance. Capability statements shall not exceed four (4) pages (8.5" x 11" format) using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. Requests for documentation, inquiries for additional information, or submissions consisting solely of questions will not be considered affirmative responses. A determination by the Government not to compete this requirement based on responses to this notice is solely within the discretion of the Government. Information received will be considered exclusively for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole-source purchase order.
Response Instructions: If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to:
• Mariangela Monsalve at mariangela.j.monsalve.civ@health.mil
• Bobbie Dobberstein at bobbie.s.dobberstein.ctr@health.mil
The closing date for challenges is no later than 1000 Pacific Daylight Time, Friday, August 28, 2026.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
mailto:mariangela.j.monsalve.civ@health.mil mailto:bobbie.s.dobberstein.ctr@health.mil
| Notice of Intent to Sole Source HT941026N0107 |
| THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. |
File details come from the government source that posted it. Updated .